Premium
EFFECT OF R219K POLYMORPHISM OF THE ABCA1 GENE ON THE LIPID‐LOWERING EFFECT OF PRAVASTATIN IN CHINESE PATIENTS WITH CORONARY HEART DISEASE
Author(s) -
Li Jia,
Wang LanFeng,
Li ZhuQin,
Pan Wei
Publication year - 2009
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2008.05119.x
Subject(s) - pravastatin , genotype , medicine , genotyping , abca1 , endocrinology , triglyceride , blood lipids , restriction fragment length polymorphism , polymorphism (computer science) , cholesterol , biology , gene , genetics , transporter
SUMMARY1 In the present study, we investigated the effects of the R219K polymorphism of the ATP‐binding cassette transporter A1 ( ABCA1 ) gene on serum lipid levels and the response to statin therapy in Chinese patients with coronary heart disease (CHD). 2 The study population consisted of 365 patients with CHD and 246 control subjects without signs or symptoms of CHD. Patients with CHD were treated with 20 mg/day pravastatin. Fasting serum lipids were determined before and after 12 weeks of treatment. Genotyping was performed by polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP). 3 The R219K polymorphism of the ABCA1 gene was not significantly associated with CHD ( P > 0.05). Compared with controls, patients with the RR genotype had significantly higher serum triglyceride levels and lower high‐density lipoprotein–cholesterol (HDL‐C) levels than those with the KK genotype ( P < 0.05). In addition, the effects of pravastatin in increasing HDL‐C levels were significantly greater in patients with the KK genotype compared with those with the RR genotype ( P < 0.05). 4 In conclusion, the R219K polymorphism of ABCA1 was associated with altered lipoprotein levels and the R219K variant significantly modulated the HDL‐C response to pravastatin in Chinese patients with CHD.